Extra Loading Dose of Dexmedetomidine Enhances Intestinal Function Recovery After Colorectal Resection: A Retrospective Cohort Study

Guo-Zun He, Ning Bu, Ya-Juan Li, Yuan Gao, Ge Wang, Zhi-Dong Kong, Min Zhao, Shan-Shan Zhang and Wei Gao

Importance: Postoperative gastrointestinal dysfunction (POGD) may be caused by postoperative vagus nerve tension inhibition and systemic inflammation. Dexmedetomidine (Dex) increases vagus nerve tone and affords an anti-inflammatory property, which may play a role in pathogenesis.

Objective: To investigate whether a higher dose of Dex enhances gastrointestinal function recovery.

Design: In this retrospective study, patients receiving colorectal surgery at the First Affiliated Hospital of Xi’an Jiaotong University from 2017 to 2019 were included. We evaluated the postoperative flatus time between recipients who received loading plus maintenance dose of DEX (LMD group, 237 recipients) and those who received maintenance dose of DEX (MD group, 302 recipients). Data were analyzed by logistic regression and stratified and interaction analyses. The simulated pharmacokinetics of two DEX regimens was compared using the Tivatrainer software. Thirty paired blood samples from patients whose propensity scores matched with POGD-related factors at 24 h postoperatively were randomly selected, and their tumor necrosis factor-α (TNF-α), cyclooxygenase-2 (COX-2), D-lactate (DLA), acetylcholine (Ach), interleukin (IL)-10, lipopolysaccharide (LPS), IL-6, and inducible nitric oxide synthase (iNOS) levels were measured.

Setting: Operating rooms and general surgery wards.

Participants: Among the 644 patients undergoing colorectal surgery, 12 who had a colostomy, 26 without Dex infusion, 20 whose Dex administration mode cannot be classified, and 47 with a history of intestinal surgery were excluded. A total of 539 patients were included.

Result: Compared with the MD group, the LMD group had a shorter recovery time to flatus; lower incidences of nausea, vomiting, abdominal distension, and abdominal pain ($p < 0.05$); and a slightly decreased heart rate. The LMD group was the independent factor.
of POGD (OR = 0.59, 95% CI = 0.41–0.87, \( p = 0.007 \)) without being reversed in stratified and interaction analyses and had higher Dex plasma concentration from skin incision to 8 h postoperatively. The LMD group had a 39% and 43% increase in Ach and IL-10 levels, respectively, and a 33%–77% decrease in TNF-\( \alpha \), IL-6, COX-2, iNOS, LPS, and DLA levels \( \left( p < 0.05 \right) \).

**Conclusion:** Adding an extra loading dose of Dex can increase parasympathetic tone and decrease inflammation; hence, it can enhance postoperative gastrointestinal function recovery following colorectal surgery.

**Keywords:** postsurgical recovery, dexmedetomidine, colorectal tumor, systemic inflammation, postoperative gastrointestinal dysfunction

### INTRODUCTION

Colorectal cancer ranked as the fourth most prevalent malignant tumor and the fifth leading cause of mortality in 2017 (Yin et al., 2019). Colorectal surgery is the frontline therapy for colorectal cancer, and the surgical outcome is considerably good with a relatively low 5-year tumor recurrence rate of 6.9% (Frontali et al., 2020). Postoperative gastrointestinal dysfunction (POGD), which affects early surgical recovery, commonly occurs after abdominal surgery (Traut et al., 2008; Millan et al., 2012). POGD is a transient impairment of gastrointestinal function after abdominal surgery and is manifested as delayed flatus and defecation, nausea, vomiting, abdominal tenderness, and abdominal distention (Mazzotta et al., 2020). The occurrence of POGD prolongs hospitalization time and increases treatment costs enormously (Vather et al., 2013; Murphy et al., 2016; Gao et al., 2021). Various strategies have been used to prevent POGD, including early postoperative feeding, avoidance of nasogastric tube use, limitation of fluid infusion, the use of minimally invasive surgery, and the use of symptomatic treatment drugs and chewing gum, but their effectiveness is limited because of the lack of pathogenesis-related targeted therapies (Bragg et al., 2015; Wolthuis et al., 2016; Wang et al., 2020; Wattchow et al., 2021).

Surgical stress and systemic inflammation are suggested to be the main causes of POGD (Bragg et al., 2015; Venara et al., 2016). POGD has two phases. In the first phase, neurogenic reflexes suppress splanchnic nerve pathways from skin incision to 3–6 h postoperatively (Stakenborg et al., 2017). In the second phase, innate pro-inflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor-\( \alpha \) (TNF-\( \alpha \)), are released because of inflammatory outbursts from 3 h after skin incision to 72 h postoperatively. In addition, other inflammatory mediators, including cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS), are increased, whereas anti-inflammatory cytokines, such as interleukin-10 (IL-10), are decreased. All of these changes can impair the intestinal barrier; moreover, lipopolysaccharide (LPS) and \( \beta \)-lactate (DLA) in the gut can be diffused into circulation and further worsen POGD (Farro et al., 2016; Stakenborg et al., 2017).

Dexmedetomidine (Dex) is a highly selective \( \alpha_2 \) receptor agonist with sedative, analgesic, anti-anxiety, sympathetic inhibitory, and less respiratory inhibitory effects (Song et al., 2016). As an auxiliary drug for general anesthesia, Dex can activate the vagal efferent system and inhibit inflammation (Wang et al., 2015; Obara, 2018; Bao and Tang, 2020). Animal studies showed that the anti-inflammatory effect of Dex is better at a high dose than at a low dose, and the effect of “pre-empty” treatment is better than that of the “post-empty” treatment (Yeh et al., 2016; Bao and Tang, 2020). A clinical research reported that the preoperative infusion of 1 \( \mu \)g/kg Dex for 10 min and the intraoperative continuous infusion of 0.3 \( \mu \)g/kg/h Dex were more beneficial to the recovery of gastrointestinal motility than without Dex (Chen et al., 2016). Although Dex is usually administered with a loading dose followed by a maintenance dose, this regimen can lower heart rate. Therefore, anesthesiologists prefer administering Dex intravenously with a loading dose followed by a maintenance dose or only as a maintenance dose during anesthesia and surgery. Based on these findings, we speculated that a relatively high dose of Dex with loading and maintenance doses may negate the pathogenesis of POGD than a maintenance dose only and, therefore, can alleviate intestinal injury and reduce POGD severity. Hence, we conducted this retrospective study, which was in accordance with the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE), to assess if the administration of a loading plus maintenance dose of Dex during surgery causes better postoperative gastrointestinal recovery than the use of its maintenance dose only.

### PATIENTS AND METHODS

**Design and Patients**

This retrospective, single-center, cohort study was the subsequent analysis of a previous clinical study (NCT03086304). Patients who underwent elective colorectal surgery at the First Affiliated Hospital of Xi’an Jiaotong University from October 2017 to December 2019 were included in the present study. The study received ethical approval from the Ethics Committee of the First Affiliated Hospital of Xi’an Jiaotong University (Approval No. XJTU1AF2016LSL-035). Data were obtained from electronic and paper records and by telephone follow-up. Patients were divided into the loading plus maintenance dose (LMD) group and maintenance dose only (MD) group according to whether they received a loading dose of Dex or not, respectively. The LMD
group was infused with a Dex loading dose of 1 μg/kg for 10 min followed by a maintenance dose of 0.4 μg/kg/h for continuous infusion. The MD group was only given a maintenance dose of 0.4 μg/kg/h. The inclusion criteria were as follows: 1) age ≥18 years with American Society of Anesthesiologists (ASA) grade I–III; 2) underwent elective colorectal surgery under general anesthesia; and 3) used Dex in general anesthesia. The exclusion criteria were as follows: 1) use of intraoperative enterostomy; 2) unclassified Dex administration dose or mode; or 3) history of intestinal surgery.

**Exposure and Outcomes**
All patients received pre-medications of 0.075 mg palonosetron, 5 mg dexamethasone, and 0.5 mg penehyclidine hydrochloride. The LMD group was initially given 1 μg/kg Dex for 10 min, and then, the dose was maintained at 0.4 μg/kg/h until the end of the operation. In comparison, the MD group was only infused with the maintenance dose of Dex throughout the surgery. After transverse abdominis plane block (TAPB; 0.375% ropivacaine 20 ml) was carried out, all patients were given 0.5 μg/kg sufentanil, 0.2 mg/kg etomidate, and 1 mg/kg rocuronium for anesthesia induction and then administered with propofol, remifentanil, and rocuronium to maintain anesthesia. Their doses were adjusted based on the bispectral index of anesthesia depth, circulatory parameters, and muscular relaxation. The surgical options, such as colectomy or proctectomy, laparoscopy or laparotomy, postoperative diet, and treatment, were made by surgeons as routine clinical practice. Intraoperative fluid management was mainly adjusted according to the vital signs and arterial blood gas results of patients. All patients in the two groups received the identical postoperative intravenous analgesia pump formula, that is, sufentanil 100 μg and dexamethasone 10 mg diluted to 100 ml with normal saline. POGD diagnosis was defined as the absence of flatulence or defecation within 3 days after surgery accompanied by symptoms such as nausea, vomiting, and abdominal distension. The primary outcome was the first postoperative flatus time, and the secondary outcomes were the first postoperative defecation time and the incidence rates of abdominal distension, abdominal pain, nausea, and vomiting within 3 days postoperatively. In our previous clinical study (Gao et al., 2021), the patients and their caregiving family members were required to accurately record the first time of occurrence of the symptoms mentioned above by filling out the patient assessment forms, which would be transcribed on an evaluation sheet in the case report form (CRF) by researchers. If the patient did not have flatus within 3 days after the operation, the researchers would continue to follow-up by telephone until the first flatus time was obtained. Abdominal pain was defined as a Visual Analogue Scale (VAS) greater than 3 (0, no pain; 10, severe pain) within 3 days after the operation. Abdominal distension was divided into five grades from 1 (no at all) to 5 (very) according to subjective feeling. When the degree was greater than 3, the patient was considered having abdominal distension.

**Dex Plasma Concentration Simulation**
The Dex pharmacokinetics of all patients from the beginning of Dex infusion to 10 h postoperatively was simulated by Tivatrainer software (version 9.1, Digital River GmbH Scheidtweilerstr, Cologne, Germany) according to the patients’ gender, age, height, weight, and ASA grade. The Dex plasma concentrations of all patients at the following time points were recorded: at 10 min, 30 min, 1 h, and 2 h post-administration; at the end of surgery; and at 2, 4, 6, 8, and 10 h postoperatively. The mean and standard deviation of plasma concentration in each group at each time point were calculated, and a pharmacokinetics chart was constructed using Origin software (Origin Lab Corporation, Northampton, America).

**Blood Sample Analysis**
The blood samples obtained from a previous clinical trial (NCT03086304) were collected and centrifuged at 4°C, and the plasma was stored at −80°C. The blood samples were harvested at 24 h postoperatively. The samples from both groups with matching propensity scores were chosen for further analyses. The preoperative and interoperative variables that had the potential to influence POGD were selected based on univariate analysis and clinical impact (e.g., gender, age, presence of chronic obstructive pulmonary disease, operation method, tumor location, and anesthesia duration) (Bragg et al., 2015; Ceretti et al., 2018). Each patient’s propensity score in the selected variables was calculated by logistic regression. Thirty paired patients were randomly selected; one patient in the LMD group was matched with one patient in the MD group. Thirty paired blood samples were obtained at 24 h postoperatively from the paired patients. Plasma TNF-α, COX-2, DLA, Ach, and IL-10 levels were determined using enzyme-linked immunosorbent assay (ELISA) kits from Shanghai Lianmai Bioengineering Co., Ltd. (Shanghai, China), and plasma LPS, IL-6 and iNOS levels were determined using ELISA kits from Cusabio Biotech Co., Ltd. (Wuhan, China).

**Statistical Analysis**
Continuous variables with normal distribution were described as mean (standard deviation, SD), whereas those with non-normal distribution were described as median (range interquartile, IQR). Categorical variables were presented as numbers (percentages, %). Continuous variables were analyzed by Student’s t-test, and categorical variables were analyzed by the chi-square test and Fisher’s exact test as appropriate. The non-parametric Mann–Whitney U test was used for the comparison of ranked data. The role of Dex was further verified by calculating the risk factors of POGD through logical regression and conducting stratification and interaction tests on the remarkably different factors between the LMD and MD groups. All statistical analyses were performed in R version 3.1.2 (R Foundation for Statistical Computing, Vienna, Austria) and Empower Stats software (X&Y Solutions, Inc., Boston, Massachusetts). p < 0.05 was considered statistically significant.
RESULTS

Perioperative Characteristics

Among the 644 patients who met the inclusion criteria, only 618 patients (95.95%) were administrated with Dex. We excluded 12 who had a colostomy, 26 without Dex infusion, 20 whose Dex administration mode cannot be classified, and 47 with a history of intestinal surgery. A total of 539 patients were included in this study. Among them, 237 patients (38.35%) were given loading plus maintenance dose (LMD group) and 302 patients (48.87%) had an infusion of maintenance dose only from anesthesia induction (MD group, Figure 1). The two groups had no statistical difference in general demographic characteristics, comorbidity, and tumor characteristics (Table 1). The intraoperative anesthesia, postoperative analgesia, surgery, and vital sign variables are presented in Table 2 and Supplementary Table S1. There was no significant difference in the dosage of opioid drugs for postoperative analgesia and the proportion of patients receiving TAPB between the two groups (95.83 ± 13.54 vs. 94.27 ± 15.95, p = 0.231; 32.07% vs. 35.43%, p = 0.413). The LMD group had more patients who underwent laparoscopic surgery and proctectomy than those in the MD group and had lower heart rates at the end of loading dose infusion (T1). As shown in Table 3, the LMD group also had remarkably shorter flatus time and lower incidence rates of nausea, vomiting, abdominal distension, and abdominal pain compared to the MD group. The incidence of POGD was lower in the LMD group than in the MD group (27.00% vs. 40.40%, p = 0.002). The proportion of patients who had flatulence within 3 days

| Variable                          | LMD group [n = 237 (43.97%)] | MD group [n = 302 (56.03%)] | P     |
|----------------------------------|------------------------------|-----------------------------|-------|
| Gender (F/M)                     | 99/138                       | 139/163                     | 0.324 |
| Age (years)                      | 61.22 ± 11.60                | 59.90 ± 12.15               | 0.205 |
| Weight (kg)                      | 62.64 ± 10.49                | 62.45 ± 10.49               | 0.834 |
| Height (cm)                      | 165.97 ± 7.18                | 165.44 ± 7.34               | 0.402 |
| BMI                              | 22.70 ± 2.94                 | 22.73 ± 3.04                | 0.906 |
| ASA grades, n (%)                |                              |                             | 0.621*|
| I                                | 14 (5.9)                     | 18 (6.0)                    |       |
| II                               | 169 (73.7)                   | 246 (81.5)                  |       |
| III                              | 34 (14.3)                    | 39 (12.5)                   |       |
| COPD, n (%)                      | 8 (3.38)                     | 12 (3.97)                   | 0.715 |
| Coronary heart disease, n (%)    | 9 (3.8)                      | 16 (5.3)                    | 0.411 |
| Diabetes, n (%)                  | 26 (11.0)                    | 27 (8.9)                    | 0.432 |
| Hypertension, n (%)              | 71 (30.0)                    | 71 (23.5)                   | 0.092 |
| Tumor size                       |                              |                             | 0.094*|
| >5 cm, n (%)                     | 51 (21.5)                    | 84 (27.8)                   |       |
| ≤5 cm, n (%)                     | 186 (78.5)                   | 218 (72.2)                  |       |
| Depth of infiltration, n (%)     |                              |                             | 0.164*|
| T0                               | 14 (5.9)                     | 12 (4.0)                    |       |
| Tis                              | 4 (1.7)                      | 0 (0)                       |       |
| T1                               | 9 (3.8)                      | 13 (4.3)                    |       |
| T2                               | 39 (16.5)                    | 40 (13.2)                   |       |
| T3                               | 74 (31.2)                    | 104 (34.4)                  |       |
| T4                               | 97 (40.9)                    | 133 (44.0)                  |       |
| Lymph node metastasis, n (%)     | 157 (66.2)                   | 194 (64.2)                  | 0.058*|
| N0                               | 46 (19.4)                    | 68 (22.5)                   |       |
| N1 (1–3)                         | 34 (14.3)                    | 34 (11.3)                   |       |
| N2 (≥4)                          | 0                            | 5 (1.7)                     |       |
| Distant metastasis, n (%)        | 10 (4.2)                     | 15 (5.0)                    | 0.676*|
| Yes                              | 227 (96.8)                   | 296 (94.7)                  |       |

Values are presented as N (column %) or Mean ± SD. *Mann–Whitney U test; **chi-square test; ‡Fisher’s exact test.
ASA, American Association of Anesthesiologists; BMI, body mass index; COPD, chronic obstructive pulmonary disease.
postoperatively was higher in the LMD group than in the MD group (73.00% vs. 59.28%, \( p = 0.037 \), Figure 2).

**Logistic Regression Analysis of Dex and POGD**

Compared with the MD group, the LMD group had an extra Dex loading dosage of 62.63 ± 10.51 μg, more laparoscopic surgery, and more proctectomy (Table 2). The LMD group was an independent protective factor of POGD (OR = 0.59, 95% CI = 0.41–0.87, \( p = 0.007 \)), but the operation method and colorectal resection were not independent risk factors (Table 4). After stratified analysis, the protective performance of the LMD group had no statistical difference in each layer (\( P \) for interaction: operation method, 0.968; colorectal resection, 0.605). The LMD group showed the significant protective effect of laparoscopy (OR = 0.60; 95% CI = 0.384–0.929, \( p = 0.022 \)) and colectomy (OR = 0.52, 95% CI = 0.322–0.828, \( p = 0.006 \)).
**DEX Plasma Concentration–Time Course Curve and Serological Indexes of POGD**

The plasma Dex concentration in the LMD group was remarkably higher than that in the MD group during operation (Figure 3) until 8 h postoperatively. The LMD group had two peaks of plasma Dex concentration. The first peak appeared at the end of load infusion, and the peak concentration (1.922 ± 0.323 ng/L) was much higher than that (0.124 ± 0.026 ng/L, \( p < 0.01 \)) in the MD group at the corresponding time point. The second peak appeared at the end of the operation (0.564 ± 0.122 ng/L vs. 0.391 ± 0.083 ng/L for the LMD and MD groups, respectively; \( p < 0.01 \)).

The biomarkers of the two groups were matched by propensity score, and there was no significant difference in confounding factors such as operation mode and resection site between the groups. Yet, the first flatus time of the LMD group was shorter than that of the MD group (Table 5). The two groups had significant differences in biomarkers at 24 h postoperatively (Figure 4). The LMD group had higher Ach (median [IQR]:124.5 [79.6, 293.6] ng/L vs. 75.7 [48.7, 100.9] ng/L, \( p = 0.000 \)) and IL-10 concentrations (134.2 [73.8, 242.4] ng/L vs. 76.7 [37.5, 111.5] ng/L, \( p < 0.001 \)) and iNOS (7.4 [4.2, 12.0] IU/ml vs. 12.1 [7.3, 19.6] IU/ml, \( p = 0.004 \)), COX-2 (4.7 [2.0, 9.0] ng/ml vs. 7.2 [5.3, 10.5] ng/ml, \( p = 0.013 \)), IL-6 (301.7 [108.1, 400.0] ng/L vs. 29.7 [19.9, 40.7] ng/L, \( p = 0.000 \)), TNF-\( \alpha \) (301.7 [108.1, 400.0] ng/L vs. 43.5 [20.9, 71.2] ng/L, \( p = 0.000 \)), LPS (37.0 [16.5, 59.5] ng/L vs. 59.7 [31.4, 89.2] ng/L, \( p = 0.000 \)), and DLA concentrations (250.3 [98.6, 427.9] \( \mu \)g/L vs. 443.7 [289.7, 657.2] \( \mu \)g/L, \( p < 0.001 \)) than the MD group.

**DISCUSSION**

The current retrospective study found that Dex use with an extra loading dose enhanced the recovery of gastrointestinal function and
decreased the biomarkers of intestinal barrier injury. Indeed, the extra loading dose of Dex remarkably reduced the postoperative flatus time by 0.5 days, as well as the incidences of postoperative nausea, vomiting, abdomen pain, and abdominal distension. The favorable effects of the extra Dex dose may be due to the higher Dex concentration in the blood from skin incision until 8 h postoperative, which likely lowered sympathetic tone, increased parasympathetic tone, and inhibited inflammation. The side effect of the extra loading
A dose of Dex was a lower heart rate, which was within the physiological range and likely had no clinical significance.

POGD is a transient gastrointestinal impairment after an abdominal surgery that compromises postoperative recovery. Current treatment strategies only limit the symptoms of POGD. Dex is widely used clinically during surgery, relieves intestinal inflammation, and protects the intestinal barrier in the intestinal ischemia–reperfusion rat model (Zhang et al., 2012). Our two groups of patients received Dex during surgery but with different administration modes and Dex dosages. The relatively higher dose of Dex was likely responsible for the favorable effects found in this study. Indeed, the patients in the LMD group had a larger dose than those in the MD group. Hence, the higher pharmacodynamics and longer pharmacokinetics may induce more drug effects against the occurrence of POGD, although more laparoscopic surgery and rectal tumor in the LMD group may also contribute to the less occurrence of POGD (Table 2). However, the logistic regression analyses showed that the extra dose of Dex but not laparoscopic surgery and colectomy was an independent protective factor (OR = 0.59; 95% CI = 0.41–0.87, p = 0.007). Laparoscopic surgery promotes the recovery of gastrointestinal function because of its minimal invasion (Wang et al., 2014). The proportional use of laparoscopic surgery in both groups was also comparably high; therefore, laparoscopy was not an independent protective factor (OR 0.69; 95% CI 0.47–1.02; p = 0.066). Our study was in line with a previous study, which reported that colectomy and proctectomy are not independent risk factors (Millan et al., 2012). Our stratified analysis further indicated that the extra loading dose of Dex was an independent protective factor.

Surgical operation activated the neurogenic stage of POGD from skin incision to 3–6 h postoperatively, in which the inhibition of vagus nerve tone widely inhibited gastrointestinal motility (Bauer and Boeckxstaens, 2004; Bragg et al., 2015; Stakenborg et al., 2017; Wattchow et al., 2021). The extra loading dose of Dex had a 4.9-fold higher peak concentration than without this dose at the end of the surgery, and its effects lasted longer up to 8 h postoperatively, which covered the neurogenic stage of POGD. This extra dose also increased plasma Ach level up to 24 h operatively and, therefore, can enhance vagus nerve tone.

Continuous intestinal inflammation prolongs the excessive excitement of the intestinal sympathetic nerve and inhibits gastrointestinal peristalsis (Bauer and Boeckxstaens, 2004; Wattchow et al., 2021). The inflammatory stage of POGD covers from 3 to 4 h intraoperatively to 72 h postoperatively (Stakenborg et al., 2017). Surgical manipulation activates macrophages in the intestinal wall; activates transcription factors, such as nuclear factor κB; causes the release of pro-inflammatory mediators (IL-6, TNF-α, COX-2, and iNOS); causes neutrophil and monocyte infiltration into the intestinal muscle layer; and releases nitric oxide and prostaglandin (Wang et al., 2018). It also destroys the pacing activity of interstitial cells of Cajal and damages the intestinal barrier (LPS and DLA) (Funder et al., 2017; Kaji et al., 2018). Previous reports suggested that Dex decreases inflammatory responses in different animal models and different types of surgeries (Li et al., 2015; Yeh et al., 2016; Wang and Li, 2018). Our study showed that the extra dose of Dex caused a higher Dex plasma concentration from skin incision up to 8 h postoperatively, which is also the time for POGD development. Therefore, the higher Dex dose inhibited the pathogenesis of POGD. The extra Dex dose also induced an increase in plasma IL-10 levels but decreased IL-6, TNF-α, COX-2, iNOS, LPS, and DLA levels. The anti-inflammatory...
effect and the enhancement of vagus nerve tone caused by Dex ultimately promoted intestinal function recovery after surgery.

The strength of our study is the relatively large sample size and the modulation of the pathogenesis of POGD using a higher dose of Dex with favorable changes in biomarker levels, which is the first report in this setting. However, this study is a retrospective one, and as such, many factors cannot be controlled; hence, the findings of the current study require further studies, including clinical trials.

In conclusion, the extra loading dose of Dex superposed with its maintaining dose can increase parasympathetic tone, decrease inflammation, and hence, promote better postoperative gut function recovery. However, the extra loading dose caused a lower heart rate, which is likely is not clinically significant (Figure 5). Therefore, the loading and maintaining administration modes of Dex should be considered for clinical use, but further studies are needed.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material; further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Ethics Committee of the First Affiliated Hospital of Xi’an Jiaotong University (Approval No. XJTU1AF2016LSL-035). The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

Study design: WG. Data collection: G-ZH, S-SZ, and MZ. Statistical analysis: Y-JL and YG. Manuscript drafting: WG, NB, G-ZH, and Z-DK. Supervision: GW and Z-DK. Project administration: WG.

FUNDING

This study was supported by the National Nature Science Foundation of China (Nos. 81771485 and 81971290), the Key Research and Development Program of Shaanxi Province (No. 2020SF-136), the Fundamental Research Funds for the Central Universities (No. xj2018262), Young Talent Support Plan of Shaanxi Province, and the Clinical Research Award of the First Affiliated Hospital of Xi’an Jiaotong University, China (No. XJTU1AF2021CRF-012).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2022.806950/full#supplementary-material

REFERENCES

Bao, N., and Tang, B. (2020). Organ-Protective Effects and the Underlying Mechanism of Dexmedetomidine. *Mediators Inflamm.* 2020, 6136105. doi:10.1155/2020/6136105

Bauer, A. J., and Boeckxstaens, G. E. (2004). Mechanisms of Postoperative Ileus. *Neuergastroenterol Motil.* 16 Suppl 2, 54–60. doi:10.1111/j.1743-3150.2004.00558.x

Bragg, D., El-Sharkawy, A. M., Psaltis, E., Maxwell-Armstrong, C. A., and Lobo, D. N. (2015). Postoperative ileus: Recent Developments in Pathophysiology and Management. *Clin. Nutr.* 34 (3), 367–376. doi:10.1016/j.clnu.2015.01.016

Ceretti, A. P., Maroni, N., Longhi, M., Giovenzana, M., Santambrogio, R., Barabino, M., et al. (2018). Risk Factors for Prolonged Postoperative Ileus in Adult Patients Undergoing Elective Colorectal Surgery: An Observational Cohort Study. *Rev. Recent Clin. Trials* 13 (4), 295–304. doi:10.2174/157488113666180521111153

Chen, C., Huang, P., Lai, L., Luo, C., Ge, M., Hei, Z., et al. (2016). Dexmedetomidine Improves Gastrointestinal Motility after Laparoscopic Resection of Colorectal Cancer: A Randomized Clinical Trial. *Medicine (Baltimore)* 95 (29), e4295. doi:10.1097/MD.0000000000004295

Farro, G., Gomez-Pinilla, P. J., Di Giovangiulio, M., Stakenborg, N., Auteri, M., Thijs, T., et al. (2016). Smooth Muscle and Neural Dysfunction Contribute to Different Phases of Murine Postoperative Ileus. *Neuergastroenterol Motil.* 28 (6), 934–947. doi:10.1111/nmm.12796

Frontali, A., Benichou, B., Valcke, I., Maggiori, L., Prost À la Denise, J., and Panis, Y. (2020). Is Follow-Up Still Mandatory More Than 5 Years after Surgery for Colorectal Cancer? *Updates Surg.* 72 (1), 55–60. doi:10.1007/s13304-019-00678-5

Funder, J. A., Tolstrup, R., Jepsen, B. N., and Iversen, L. H. (2017). Postoperative Paralytic Ileus Remains a Problem Following Surgery for Advanced Pelvic Cancers. *J. Surg. Res.* 218, 167–173. doi:10.1016/j.jss.2017.05.044

Gao, W., Li, W., Yan, Y., Yang, R., Zhang, Y., Jin, M., et al. (2021). Transcutaneous Electrical Acupoint Stimulation Applied in Lower Limbs Decreases the Incidence of Paralytic Ileus after Colorectal Surgery: A Multicenter Randomized Controlled Trial. *Surgery* 170 (6), 1618–1626. doi:10.1016/j.surg.2021.08.007

Kaji, N., Nakayama, S., Horiguchi, K., Inou, S., Ozaki, H., and Hori, M. (2018). Disruption of the Pacemaker Activity of Intestinal Cells of Caja via Nitric Oxide Contributes to Postoperative Ileus. *Neuergastroenterol Motil.* 30, e13334. doi:10.1111/nmo.13334

Li, B., Li, Y., Tian, S., Wang, H., Wu, H., Zhang, A., et al. (2015). Anti-Inflammatory Effects of Perioperative Dexmedetomidine Administered as an Adjunct to General Anesthesia: A Meta-Analysis. *Sci. Rep.* 5, 12342. doi:10.1038/srep12342

Mazzotta, E., Villalobos-Hernandez, E. C., Fiorda-Diaz, J., Harzaman, A., and Christofi, F. L. (2020). Postoperative Ileus and Postoperative Gastrointestinal Tract Dysfunction: Pathogenic Mechanisms and Novel Treatment Strategies beyond Colorectal Enhanced Recovery after Surgery Protocols. *Front. Pharmacol.* 11, 583422. doi:10.3389/fphar.2020.583422

Millan, M., Biondo, S., Fracalvieri, D., Frago, R., Golda, T., and Kreider, E. (2012). Risk Factors for Prolonged Postoperative Ileus after Colorectal Cancer Surgery. *World J. Surg.* 36 (1), 179–185. doi:10.1007/s00268-011-1339-5

Murphy, M. M., Tevis, S. E., and Kennedy, G. D. (2016). Independent Risk Factors for Prolonged Postoperative Ileus Development. *J. Surg. Res.* 201 (2), 279–285. doi:10.1016/j.jss.2015.10.047

Obara, S. (2016). Dexmedetomidine as an Adjuvant during General Anesthesia. *J. Anesth.* 32 (3), 313–315. doi:10.1007/s00540-018-2509-5
Song, J., Ji, Q., Sun, Q., Gao, T., Liu, K., and Li, L. (2016). The Opioid-Sparing Effect of Intraoperative Dexmedetomidine Infusion after Craniotomy. J. Neurosurg. Anesthesiol 28 (1), 14–20. doi:10.1097/ansa.0000000000000190

Stakenborg, N., Gomez-Pinilla, P. J., and Boeckxstaens, G. E. (2017). Postoperative Ileus: Pathophysiology, Current Therapeutic Approaches. Handb Exp. Pharmacol. 239, 39–57. doi:10.1007/164_2016_108

Traut, U., Brügger, L., Kunz, R., Pauli-Magnus, C., Haug, K., Bucher, H. C., et al. (2013). Deoxymethionine (DMD) promotes intestinal function recovery. J. Gastrointest. Surg. 17 (5), 962–972. doi:10.1007/s11605-013-2148-y

Venara, A., Neuß, M., Slim, K., Barbieux, J., Colas, P. A., Hamy, A., et al. (2016). Postoperative ileus: Pathophysiology, Incidence, and Prevention. J. Vis. Surg. 153 (6), 439–446. doi:10.1016/j.jvisuitsurg.2016.08.010

Wang, C. L., Qu, G., and Xu, H. W. (2014). The Short- and Long-Term Outcomes of Laparoscopic versus Open Surgery for Colorectal Cancer: A Meta-Analysis. Int. J. Colorectal Dis. 29 (3), 309–320. doi:10.1007/s00384-013-1827-1

Wang, J., Li, D., Tang, W., Guo, J., Chen, W., Yong, Y., et al. (2020). Pretreatment with Transcutaneous Electrical Acupoint Stimulation to Prevent Postoperative Ileus in Patients Undergoing Laparoscopic Colon Surgery: Study Protocol for a Randomised Controlled Trial. BMJ open 10 (8), e030694. doi:10.1136/bmjopen-2019-030694

Wang, K., and Li, C. (2018). Effects of Dexmedetomidine on Inflammatory Factors, T Lymphocyte Subsets and Expression of NF-Kb in Peripheral Blood Mononuclear Cells in Patients Receiving Radical Surgery of Colon Carcinoma. Oncol. Lett. 15 (5), 7153–7157. doi:10.3892/ol.2018.8205

Wang, W., Chen, M., Jin, X., Li, X., Yang, Z., Lin, H., et al. (2018). H2S Induces Th1/Th2 Imbalance with Triggered NF-Kb Pathway to Exacerbate LPS-Induce Chicken Pneumonia Response. Chemosphere 208, 241–246. doi:10.1016/j.chemosphere.2018.05.152

Wang, Y., Xu, X., Liu, H., and Ji, F. (2015). Effects of Dexmedetomidine on Patients Undergoing Radical Gastrectomy. J. Surg. Res. 194 (1), 147–153. doi:10.1016/j.jss.2014.10.008

Watchow, D., Heitmann, P., Smolliho, D., Spencer, N. J., Parker, D., Hibberd, T., et al. (2021). Postoperative Ileus–An Ongoing Conundrum. Neurogastroenterol Motil. 33 (5), e14046. doi:10.1111/nmo.14046

Wolthuis, A. M., Bislenghi, G., Fieuws, S., de Buck van Overstraeten, A., Boeckxstaens, G., and D’Hoore, A. (2016). Incidence of Prolonged Postoperative Ileus after Colorectal Surgery: A Systematic Review and Meta-Analysis. Colorectal Dis. 18 (1), O1–O9. doi:10.1111/codi.13210

Yeh, Y. C., Wu, C. Y., Cheng, Y. J., Liu, C. M., Hsiao, J. K., Chan, W. S., et al. (2016). Effects of Dexmedetomidine on Intestinal Microcirculation and Intestinal Epithelial Barrier in Endotoxemic Rats. Anesthesiology 125 (2), 355–367. doi:10.1097/alan.0000000000001135

Yin, J., Bai, Z., Zhang, J., Zheng, Z., Yao, H., Ye, P., et al. (2019). Burden of Colorectal Cancer in China, 1990–2017: Findings from the Global Burden of Disease Study 2017. Chin. J. Cancer Res. 31 (3), 489–498. doi:10.21147/j.issn.1000-9604.2019.03.11

Zhang, X. Y., Liu, Z. M., Wen, S. H., Li, Y. S., Li, Y., Yao, X., et al. (2012). Dexmedetomidine Administration before, but Not after, Ischemia Attenuates Intestinal Injury Induced by Intestinal Ischemia-Reperfusion in Rats. Anesthesiology 116 (5), 1035–1046. doi:10.1097/ALN.0b013e3182503964

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 He, Bu, Li, Gao, Wang, Kong, Zhao, Zhang and Gao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.